Healthcare & Life Sciences
Kainova Therapeutics
Canada
series-b
series-b
Stage
1
Investors
About
Kainova Therapeutics is a clinical-stage company developing therapies that target G protein-coupled receptors (GPCRs) for immuno-oncology and inflammatory diseases. Its lead programs include DT-7012 (an anti-CCR8 Treg-depleting antibody), DT-9046 (a preclinical biased PAR2 antagonist), and DT-9081 (a Phase II-ready EP4 receptor antagonist for solid tumors).
Explore Kainova Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.